CRON

Good morning. My name is Michelle. I will be your conference operator today. I would like to welcome everyone to the Cronos 2026 first quarter conference call. Today's call is being recorded. At this time, I would like to turn the call over to Harrison Aaron, Senior Director, Investor Relations and Corporate Development. Please go ahead, sir.

Thank you, Michelle, and thank you for joining us today to review Cronos's 2026 Q1 financial and business performance. Today, I am joined by our Chairman, President, and CEO, Mike Gorenstein, and our CFO, Anna Shlimak. Cronos issued a news release announcing our financial results this morning, which is filed on our EDGAR and SEDAR profiles. This information and the prepared remarks will also be posted on our website under Investor Relations. Before I turn the call over to Mike, let me remind you that we may make forward-looking statements and refer to non-GAAP financial measures during this call. These forward-looking statements are based on management's current expectations and assumptions that are subject to risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements.

Factors that could cause actual results to differ materially from expectations are detailed in our earnings materials and our SEC filings that are available on our website, by which any forward-looking statements made during this call are qualified in their entirety. Information about non-GAAP financial measures, including reconciliations to US GAAP, can also be found in the earnings materials that are available on our website. Lastly, we will be making statements regarding market share information throughout this conference call, and unless otherwise stated, all market share data is provided by Hifyre. We will now make prepared remarks, and then we'll move to a question-and-answer session.

With that, I'll pass it over to Cronos's Chairman, President, and CEO, Mike Gorenstein.

Thanks, Harrison. Cronos delivered record net revenue and gross profit in Q1 2026 as we continue to execute on our strategic vision. International markets delivered record net revenue, and our Canadian brands posted share gains across key categories, led by Spinach achieving the number 1 market share position in vapes. Starting with Cronos Israel, in Q1, we delivered our ninth consecutive quarter of record net revenue, growing 53% year-over-year. We extended our market share lead, powered by Peace Naturals as the number 1 brand in Israel, according to pharmacy data collected by Cronos. This performance was driven by the quality of our genetics and the execution of our team on the ground. We are also very pleased with the initial performance of the Lord Jones brand in Israel.

We launched the brand with a lineup of curated premium flower offerings featuring cold-cured large flower buds in a series of limited time drops. The initial reception has been strong, demonstrating that the Lord Jones brand's premium positioning translates across markets. We're looking forward to building upon this early momentum. Between PEACE NATURALS, LIT, and Lord Jones, we now offer Israeli pharmacies a comprehensive tiered product portfolio that addresses a spectrum of patient price points and broadens our market reach. Turning to Canada, our brands generated 18% year-over-year retail sales growth relative to industry-wide sales growth of 2%, according to Hifyre. The Spinach brand had an excellent quarter, with our product portfolio demonstrating the success of our innovation efforts through substantial share gains. Spinach ranked number one across all vape formats in Q1, capturing 9.8% total market share.

In vape cartridges specifically, Spinach held an 11.1% share, also the number 1 position. Adding to that achievement, the 3 best-selling vape SKUs in the country this quarter were all Spinach cartridges. This is a meaningful milestone that reflects our ongoing investment in product quality and innovation while leaning on consumer insights to guide our product development pipeline. On that note, Spinach PUFFERZ continue to build distribution and disrupt the market in Q1, broadening its presence across Canadian provinces after its initial launch in select markets late last year. PUFFERZ reached the number 2 market share position in the all-in-one vape category in March 2026, just 4 months after launch. PUFFERZ exemplifies what we mean when we talk about raising the bar on product excellence, design, and flavor, and the early consumer response has validated our conviction in the PUFFERZ platform.

In edibles, we maintained our number 1 position with 20.8% market share, with gummies at 22.7%. SOURZ by Spinach remains the clear category leader in edibles, with the Fully Blasted multipack leading the charge. Launched in mid-2025, the Fully Blasted offerings now occupy 4 of the top 10 edible SKUs in Canada, including the number 1 SKU nationwide in Q1. In flower, quarter-over-quarter, we rose in the ranks from number 4 to number 3, which is a direct reflection of the easing of our supply constraints following the completion of the Cronos GrowCo expansion. We said last quarter that we expected supply constraints to ease in 2026, and we're starting to see that play out. In the pre-roll category, we introduced Spinach STIX, the brand's first cylindrical style pre-roll, responding to strong consumer demand for this fast-growing format.

We launched three stick SKUs in GMO Cookies, Sour Chem, and Space Cake, alongside new 2-by-1 gram pre-rolls in Sour Chem and GMO Cookies. Together, these launches helped Spinach climb to the number 8 market share position in non-infused pre-rolls in Q1. Turning to our other international markets, we delivered 97% year-over-year growth, posting record net revenue in the quarter, driven by sustained momentum in Germany. Our PEACE NATURALS and LIT brands remain the engine of our international performance, and the breadth of our footprint across markets provides significant further growth potential and optionality as regulatory environments evolve. Building on our international momentum, we remain very excited about our pending acquisition of CanAdelaar. We announced the definitive agreement in December and are prepared to close subject to certain closing conditions, with completion of the transaction expected in summer of 2026.

As a reminder, CanAdelaar are the largest company operating within the Netherlands legal adult use cannabis program and the only industrial-scale greenhouse cultivator. The Netherlands has a deep cannabis heritage, and we believe this market has the potential to serve as a model for other European markets. Acquiring a market leader in Europe's largest adult use cannabis market is an important step in our international strategy and an opportunity to deploy our borderless product strategy at scale. We're excited to bring CanAdelaar our end of the Cronos family and build on the foundation it has established. Cronos maintains the strongest balance sheet in the industry, with no debt and CAD 822 million in cash and cash equivalents, allowing us to continue investing in growth, innovation and global expansion. Today, we announced our board's authorization of a renewed CAD 50 million share repurchase program.

This decision reflects our belief in the long-term value of our business and our commitment to delivering returns to shareholders as we execute on our strategy. Given our balance sheet and profitability, we have the opportunity to invest across organic growth, share repurchases, and M&A.

Now I'll turn it over to Anna to walk you through our first quarter financials.

Thanks, Mike. Good morning, everyone. I'll now review our first quarter 2026 results. The company reported consolidated net revenue of CAD 45.2 million, a 40% increase year-over-year. The net revenue increase was driven by higher cannabis flower sales in Israel, Canada, and other countries, and higher cannabis extract sales in the Canadian market. Gross profit and adjusted gross profit in the first quarter were CAD 19.2 million, representing a 39% year-over-year growth from Q1 2025's adjusted gross profit. The year-over-year increase was primarily due to higher sales volumes and higher average sales prices, largely driven by a mix shift to Israel and other countries which carry no excise tax.

Operating expenses excluding restructuring costs and impairments were CAD 20.5 million in the quarter, a year-over-year increase of CAD 3.3 million, driven by increases in G&A, sales and marketing, and R&D expenses. Note that CAD 1.3 million of the increase in G&A within OpEx is due to discrete costs primarily related to transaction costs incurred in connection with the CanAdelaar acquisition. Adjusted EBITDA in the first quarter was CAD 5.1 million, an improvement of CAD 2.8 million year-over-year, driven by higher gross profit, partially offset by higher operating expenses. Turning to the balance sheet and cash flow statement.

The company ended the quarter with CAD 822 million in cash equivalents and short-term investments, down CAD 10 million from Q4 2025, driven by CAD 17 million of share repurchases, CAD 2 million of CapEx spend, and CAD 2 million of withholding taxes paid on share-based compensation, partially offset by positive cash flow from operations before changes in working capital of CAD 11 million. In addition to this cash balance, we hold CAD 21 million of loans receivable and CAD 5 million of other investments. In summary, we delivered record net revenue and record gross profit in Q1, with strong gross margins and adjusted EBITDA that was the second-highest in company history. It is a reflection of the underlying strength of our business and the team's continued focus on execution.

With that, I'd like to hand it back to Mike for a brief comment before Q&A.

Thanks, Anna. Q1 was a strong start to 2026, with record net revenue and record gross profit. In Canada, Spinach reaching number 1 in vapes for the first time while maintaining or advancing its market-leading position in all the categories we participate in. Cronos Israel delivered another record quarter, and our international markets outside Israel nearly doubled year-over-year. We are building something differentiated: a branded portfolio of innovative products that resonate with consumers in any market, underpinned by an expanding and efficient production platform and the strongest balance sheet in the industry. The Cronos GrowCo expansion is now online. We expect to close the CanAdelaar acquisition to add Europe's largest adult-use cannabis business to our footprint this summer, and we enter the balance of 2026 with momentum, financial flexibility, and a team that knows how to execute.

Thank you. We'll now open the line for questions.

Thank you. To ask a question, please press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. We ask that you please limit yourselves to 1 question and 1 follow-up before reentering the queue. 1 moment for our first question. Our first question will come from the line of Kenric Tyghe with Canaccord Genuity Capital Markets. Your line is open. Please go ahead.

Thank you. Good morning, congrats on the quarter. Mike, quick question for you on the GrowCo expansion and that ramp. Just in terms of your targeted efficiency and throughput, where do you think you are on that journey today, and how is that tracking against your expectations?

Thanks. That's a great question. I think that, you know, we've seen a certainly a jump in efficiency and progress from last quarter to this quarter. I think you've seen kind of like a bulk of us getting things online, you know, and working through the ramp-up. You know, there's still some efficiencies that we'll dial in over the coming quarters. As far as being planted and having the throughput, we're there now.

Appreciate it. Thank you. Then just a quick pivot. With respect to the extension on the long stop date on CanAdelaar, just an abundance of caution on the extension through September so this doesn't become sort of an iterative process. Do you think, balance of probabilities, there is a chance that this does only close in the 3rd quarter versus, late in the 2nd?

Yeah. I think that's an abundance of caution. You know, we haven't seen anything that would cause any issues. I think it's certainly taking time, but we've already seen multiple licensed producers in the experiment get approval, and it's really just I think a question of waiting for BBAB to process. We're confident in the process, and there's no issues that we've seen.

Great. Thank you. I'll get back in queue.

Thank you, and one moment for our next question. Our next question will come from the line of Bill Kirk with ROTH Capital Partners. Your line is open. Please go ahead.

Hey, good morning, everybody. Mike, I'd love your perspective on the rescheduling news in the U.S. and maybe how it impacts how you think about that market and Cronos plans to participate or not participate or be involved. Maybe we could start there under your perspective of the rescheduling announcement so far.

Sure, yeah. I'd say it's very, very exciting announcement and development, and one of the most significant milestones in the U.S. regulatory environment that we've seen in the last 10 years. You know, as always, I think that the devil will be in the details, and there's still some things that need to be worked out. We're very optimistic, and I think that when you compare, you know, how this was announced and what, you know, early indications look like compared to maybe the last few iterations of rescheduling, this seems very positive. We're continuing to monitor and, you know, figure out what the best spot for us is.

I would say that really what I'm focused on is what opportunities the, you know, end up being created from a interstate perspective and then also an international perspective. You know, I think that how state laws end up changing and how some of those details work out will really dictate where we move in.

Okay. If I can, another on the, you know, the capacity expansion in GrowCo and maybe how that product ultimately gets allocated. Where is GrowCo in its or the expansion of GrowCo, where is it in its kind of maturity? Like, what is it able to do today versus what you think it can do, you know, I don't know, a year from now?

I think, you know, we talked about this in the initial, you know, when we projected it forward that, you know, we would have the first, you get through a first harvest or 2 harvests, and that ramp up is a big step. Since we've been past that, we're now in the phase where it's how, you know, each harvest after that efficiency dials in in the 1st year. You're looking at like, you know, smaller percentage gains. There wouldn't be massive changes, of course, you know, depending on what the season is, you know, light can affect yields. I think that we can now move back to how do we dial in efficiencies and increase yields versus how do we get everything planted, get everything harvested.

You know, you can expect some efficiency gains and some extra yields, but it's not gonna be, I think, a dramatic step change.

Thank you. I'll pass it along.

Thank you, and one moment for our next question. Our next question comes from the line of Derek Lessard with TD Cowen. Your line is open. Please go ahead.

Good morning, Mike and Anna. Congrats on a really strong quarter. I guess I just wanted to touch on your number one market share. Just maybe talk about, Mike, the specific levers behind the share gains and what do you think your playbook looks like from here?

Thanks. Yeah, I assume you're referring to Canada. I'm not sure which market.

Yeah, Canada, Mike. Yeah, sorry.

Oh, yeah. Look, I think a big thing that affects share for us is obviously in flower and, you know, what availability we have. We're always in this sort of back and forth of do we have enough, you know, capacity to allocate to all the markets? How do we allocate among the markets? I think this quarter you saw us have, because of the increase in capacity, more flower available to Canada, and that allowed us to fill a lot of unconstrained demand. You know, I still think that you'll see more unconstrained demand.

Then with things growing also, though, in, you know, in Israel and, you know, in Europe, that'll just be something that quarter to quarter we'll have to look at how we allocate and really optimize overall for margin. I think that a big change was also what, you know, what we were able to do with vapes. You know, the biggest innovation, biggest change came down to PUFFERZ. It's been something we've been working on for a long time, and we haven't really been a meaningful participant in all-in-one vapes, which is a really big category. That's just you're seeing that momentum, and I think you're gonna see that momentum continue, you know, throughout the year.

Now we, you know, we think the big lever for us to pull is gonna be in pre-rolls, where we still have some work to do.

Awesome. I guess, given the success, I was curious if you can maybe just comment on some of the competitive intensity, again, within Canada and within those categories that you're seeing and how you're working to, you know, given your strength, but maybe just protecting your margins?

Yeah, I think, you know, we've seen more, I'd say we've seen tougher competitive dynamics than we're seeing now just because of a lot of the pull that goes to Europe and certainly depends on the categories. I think that as we continue to scale, that, you know, we get better fixed cost absorption. You know, we're able to get costs down, and that allows us to have the flexibility to compete, you know, as needed. We don't feel like it's sort of in the same deflationary environment that it was in the past.

Thanks, Mike.

Thank you. One moment for our next question. Our next question will come from the line of Pablo Zuanic with Zuanic & Associates. Your line is open. Please go ahead.

Thank you, and good morning, everyone. Mike, can you comment regarding the Netherlands, on market conditions there in the pilot towns regarding either market size, growth trends, competitive dynamics, pricing? Also in the same topic, the summer review is supposed to be completed soon, and would you expect any changes from that, like either more licenses issued to more licensed producers or more towns added to the pilot? Thanks.

Sure. Thanks. I think that you've seen a little bit of competition heating up because you had one of the licensed producers that wasn't online come online. You've seen some of the companies, you know, dial in efficiencies, you're also seeing the market growing a bit. From a competitive dynamic, it's not really as intense as what you've seen in Canada or Israel. I think that there's still a ways to go as far as kind of innovation in the market and, you know, that's something that will come with the maturity. You know, you may see some changes in stores in one of the municipalities where you'll have a few that come offline, a few more stores will be opening.

In Groningen, there'll be a few that shut down and then open up, but net, we should be gaining stores. That'll play out over the next, you know, year or so. I don't know if it's something that you'll see that'll be a big enough impact to the market, one way or the other, but there will be some movement on stores there. I don't expect changes from the summer review. I think that's really more about showing the data of how the program's going. I think the program's been going very well, and that's really just something that's gonna help propel things forward for the future.

All right. Thank you. Just a quick follow-up. I know this is probably a question more for Altria, but now with the CEO change, Sal taking over from Billy, you know, potential implications for Cronos or maybe if you can talk about, you know, your interaction with the prior CEO and the new CEO. Whatever color you can give, it would be helpful, especially in the context of BAT being so active in this space through its affiliates in terms of M&A. Thanks.

Yeah, I think, we have a great relationship with Sal. You know, we've known There's a lot of continuity at Altria, so we've known the management teams and, you know, we don't see any change. I think that, you know, when you look at the activity, part of why, maybe why it looks like Altria is less active is we just haven't had a need for additional capital. That, you know, means sort of less actions on their part. You know, they're still involved through the board. We're still in constant dialogue, and I think, everyone's very pleased with the progress and what's going on.

Thank you. If I may, I know it's only two questions, but I want to add just one more. In terms of how you coordinate your international strategy between Cronos GrowCo and Cronos, is that like one company together operating overseas, or is there some competition between the two? Can you just give color on that? Thank you.

We're, we're pretty closely aligned. I mean, it's, you know, because of the board dynamics, because of just operationally how we work together, you know, there's pretty close coordination. You know, we share the same, the same Cronos name, same genetics, same, you know, same products, same governance. I'd say it's a very, very close relationship and closer to one company than two separate.

Thank you.

Thank you. One moment for our next question. We have a follow-up question from the line of Derek Lessard with TD Cowen. Your line is open. Please go ahead.

Yeah, Mike, just one follow-up from me. PEACE NATURALS brand still clearly resonating with consumers. Maybe just talk about the market dynamics in Israel and some of the opportunities you guys are seeing in that market.

Yeah, I think Israel's been a, you know, kind of unique situation for a year now, I'm sorry, for more than a year. I think that staying consistent is really, really important. You know, patients there really wanna see that you have the same product quality available, and for us, being able to keep that has been really strong. I think that there's, you know, there are new strains that we're able to introduce, but we do so carefully and making sure that we can be consistent with them. That's really a key difference in a medical market, you know, making sure that availability is there. You know, there are other formats that were looked at, but really its genetics that I think drive the most differentiation.

I think that beyond PEACE NATURALS, also Lord Jones is a really incremental opportunity for us. Now being able to have not just kind of a value in mainstream offering, but having premium just allows us to have more offerings when we go to the different pharmacies and just strengthen their distribution footprint.

Awesome. Thanks, Mike, and congrats again.

Thank you. Ladies and gentlemen, this does conclude today's question and answer session. This will also conclude today's conference call. Thank you for participating, and you may now disconnect. Everyone, have a great day.